These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33469686)

  • 21. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis.
    Rama S; Suh CH; Kim KW; Durieux JC; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2022 Apr; 218(4):602-613. PubMed ID: 34704461
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.
    Derlin T; Peldschus K; Münster S; Bannas P; Herrmann J; Stübig T; Habermann CR; Adam G; Kröger N; Weber C
    Eur Radiol; 2013 Feb; 23(2):570-8. PubMed ID: 22843058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
    van Lammeren-Venema D; Regelink JC; Riphagen II; Zweegman S; Hoekstra OS; Zijlstra JM
    Cancer; 2012 Apr; 118(8):1971-81. PubMed ID: 21887677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Significance of 18F-FDG PET/CT Imaging Coupled with Magnetic Resonance Imaging of the Entire Body for Bone Metastases.
    Guo H; Zhang Z; Wang L; Yao S; Xu S; Ma S; Liu S
    Contrast Media Mol Imaging; 2022; 2022():7717398. PubMed ID: 36247843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Updates in the Role of Imaging for Multiple Myeloma Management Based on Recent International Guidelines.
    Lee K; Kim KW; Ko Y; Park HY; Chae EJ; Lee JH; Ryu JS; Chung HW
    Korean J Radiol; 2021 Sep; 22(9):1497-1513. PubMed ID: 34448381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
    Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
    Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
    Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
    Pfannenberg C; Aschoff P; Schanz S; Eschmann SM; Plathow C; Eigentler TK; Garbe C; Brechtel K; Vonthein R; Bares R; Claussen CD; Schlemmer HP
    Eur J Cancer; 2007 Feb; 43(3):557-64. PubMed ID: 17224266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.
    Jamet B; Necib H; Carlier T; Frampas E; Bazin J; Desfontis PH; Monnet A; Bodet-Milin C; Moreau P; Touzeau C; Kraeber-Bodere F
    Cancer Imaging; 2024 Jul; 24(1):93. PubMed ID: 38992707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
    Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
    Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    Zhang C; Liang Z; Liu W; Zeng X; Mo Y
    BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Hemrom A; Tupalli A; Alavi A; Kumar R
    PET Clin; 2022 Jul; 17(3):415-430. PubMed ID: 35717100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
    Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
    Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
    Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.